Arrowhead Pharmaceuticals Is Maintained at Neutral by Citigroup

Dow JonesNov 27 10:34 ET · Ratings

Express News | Arrowhead Pharmaceuticals Shares up 6.2% ; at Least Two Brokerages Raise PT After Licensing Deal With Sarepta

ReutersNov 27 09:36 ET

Arrowhead Pharmaceuticals Shares Are Trading Higher. Chardan Capital Maintained a Buy Rating on the Stock.

BenzingaNov 27 08:35 ET

Express News | Arrowhead Pharmaceuticals Shares Are Trading Higher. Chardan Capital Maintained a Buy Rating on the Stock

BenzingaNov 27 08:35 ET

RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $42

Moomoo NewsNov 27 08:31 ET · Ratings

Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsNov 27 08:31 ET · Ratings